US Edition
Obesity drug prices are dropping, but getting a steady supply remains a challenge
UNITED STATES AND UNITED KINGDOM, JUL 7 – Drug prices for obesity treatments like Wegovy and Zepbound have declined due to competition and new developments, but supply shortages and uneven insurance coverage keep access limited.
- On July 1, CVS Health dropped Eli Lilly's obesity drug Zepbound from its national formulary and favored Novo Nordisk's Wegovy.
- This shift occurred amid ongoing price competition, growing demand for GLP-1 obesity drugs, and coverage limitations driven by high costs.
- Prices for Wegovy and Zepbound have fallen to about $500 monthly for uninsured patients, while many face inconsistent insurance coverage and high discontinuation rates.
- Experts note that price wars and the introduction of pill versions could further reduce costs, but obstacles such as lawsuits over compounded drugs and limited patient access remain.
- The event highlights broader challenges in obesity treatment access, suggesting price pressures and coverage shifts may shape the market's future sustainability.
100 Articles
100 Articles
Wegovy and Zepbound Prices Fall, but Access to the Obesity Drugs Still Isn’t Guaranteed
Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging. The medications still amount to around $500 per month for those without insurance — out of reach for many patients. And even for people with insurance, coverage remains uneven. “The medications should be available, the question is at what price and can people sustain that,” said Matt Maciejewski, a Duke University profes…
Company works to expand access to legitimate obesity solutions
JACKSON, Tenn. — Obesity medications, once facing shortages, are now widely available. You see advertisements for them online, especially on social media. While these medications are available, some patients still face challenges due to cost and insurance coverage. So how do consumers not get scammed into purchasing knockoff versions that may not be effective or safe? Living with obesity can have serious effects on the body, both physically and …
Coverage Details
Bias Distribution
- 78% of the sources are Center
To view factuality data please Upgrade to Premium
